COSMED receives Innovative Technology Designation from Vizient for K5 Wearable Metabolic System
Concord (California, USA) - November 2017 - COSMED announced its K5 Wearable Metabolic System has received a 2017 Innovative Technology designation from Vizient, Inc., the largest member-driven health care performance improvement company in the country.
The designation was based on direct feedback from hospital experts who interacted with the K5 Wearable Metabolic System at the Vizient Innovative Technology Exchange in Denver on September 14, 2017.
The COSMED K5 Wearable Metabolic System is used in professional healthcare facilities to measure cardio-respiratory and metabolic functions during stress testing, rehabilitation, sports medicine, and other related activities. The K5 represents the latest generation of COSMED's wearable metabolic systems, first introduced over 25 years ago.
"The new K5 represents a breakthrough in metabolic assessment, as it provides the most advanced technology available today within a single device that can be used both in a lab or in the field," states Claudio Bellini, COSMED USA Director of Business Development.
"Hospitals and providers are looking for innovations that offer unique and cumulative benefit over other products available on the market today. The feedback on the K5 Wearable Metabolic System by attendees at our Innovative Technology Exchange was strongly in favor of assigning this technology an Innovative Technology designation. Congratulations to COSMED on receiving this status," said Debbie Archer, director of procurement and Vizient Innovative Technology Program lead.
Vizient represents a diverse membership base that includes academic medical centers, pediatric facilities, community hospitals, integrated health delivery networks and non-acute health care providers, and represents more than $100 billion in annual purchasing volume. Through its Innovative Technology Program, Vizient works with member-led councils and task forces to review potentially innovative products. If it is determined that a product is innovative, Vizient may award a contract outside of the competitive bid cycle.
